Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.
Identifieur interne : 002372 ( PubMed/Curation ); précédent : 002371; suivant : 002373Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.
Auteurs : Petra Rzepecki [États-Unis] ; Luitgard Nagel-Steger ; Sophie Feuerstein ; Uwe Linne ; Oliver Molt ; Reza Zadmard ; Katja Aschermann ; Markus Wehner ; Thomas Schrader ; Detlev RiesnerSource :
- The Journal of biological chemistry [ 0021-9258 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Centrifugation en gradient de densité, Fragments peptidiques (), Fragments peptidiques (génétique), Fragments peptidiques (métabolisme), Humains, Liaison hydrogène, Ligands, Maladie d'Alzheimer (anatomopathologie), Maladie d'Alzheimer (métabolisme), Modèles moléculaires, Peptides bêta-amyloïdes (), Peptides bêta-amyloïdes (génétique), Peptides bêta-amyloïdes (métabolisme), Pyrazoles (), Pyrazoles (métabolisme), Spectrométrie de fluorescence (), Structure moléculaire, Structure quaternaire des protéines, Structure secondaire des protéines.
- MESH :
- anatomopathologie : Maladie d'Alzheimer.
- génétique : Fragments peptidiques, Peptides bêta-amyloïdes.
- métabolisme : Fragments peptidiques, Maladie d'Alzheimer, Peptides bêta-amyloïdes, Pyrazoles.
- Animaux, Centrifugation en gradient de densité, Fragments peptidiques, Humains, Liaison hydrogène, Ligands, Modèles moléculaires, Peptides bêta-amyloïdes, Pyrazoles, Spectrométrie de fluorescence, Structure moléculaire, Structure quaternaire des protéines, Structure secondaire des protéines.
English descriptors
- KwdEn :
- Alzheimer Disease (metabolism), Alzheimer Disease (pathology), Amyloid beta-Peptides (chemistry), Amyloid beta-Peptides (genetics), Amyloid beta-Peptides (metabolism), Animals, Centrifugation, Density Gradient, Humans, Hydrogen Bonding, Ligands, Models, Molecular, Molecular Structure, Peptide Fragments (chemistry), Peptide Fragments (genetics), Peptide Fragments (metabolism), Protein Structure, Quaternary, Protein Structure, Secondary, Pyrazoles (chemistry), Pyrazoles (metabolism), Spectrometry, Fluorescence (methods).
- MESH :
- chemical , chemistry : Amyloid beta-Peptides, Peptide Fragments, Pyrazoles.
- chemical , genetics : Amyloid beta-Peptides, Peptide Fragments.
- metabolism : Alzheimer Disease, Amyloid beta-Peptides, Peptide Fragments, Pyrazoles.
- methods : Spectrometry, Fluorescence.
- pathology : Alzheimer Disease.
- Animals, Centrifugation, Density Gradient, Humans, Hydrogen Bonding, Ligands, Models, Molecular, Molecular Structure, Protein Structure, Quaternary, Protein Structure, Secondary.
Abstract
A new concept is introduced for the rational design of beta-sheet ligands, which prevent protein aggregation. Oligomeric acylated aminopyrazoles with a donor-acceptor-donor (DAD) hydrogen bond pattern complementary to that of a beta-sheet efficiently block the solvent-exposed beta-sheet portions in Abeta-(1-40) and thereby prevent formation of insoluble protein aggregates. Density gradient centrifugation revealed that in the initial phase, the size of Abeta aggregates was efficiently kept between the trimeric and 15-meric state, whereas after 5 days an additional high molecular weight fraction appeared. With fluorescence correlation spectroscopy (FCS) exactly those two, i.e. a dimeric aminopyrazole with an oxalyl spacer and a trimeric head-to-tail connected aminopyrazole, of nine similar aminopyrazole ligands were identified as efficient aggregation retardants whose minimum energy conformations showed a perfect complementarity to a beta-sheet. The concentration dependence of the inhibitory effect of a trimeric aminopyrazole derivative allowed an estimation of the dissociation constant in the range of 10(-5) m. Finally, electrospray ionization mass spectrometry (ESI-MS) was used to determine the aggregation kinetics of Abeta-(1-40) in the absence and in the presence of the ligands. From the comparable decrease in Abeta monomer concentration, we conclude that these beta-sheet ligands do not prevent the initial oligomerization of monomeric Abeta but rather block further aggregation of spontaneously formed small oligomers. Together with the results from density gradient centrifugation and fluorescence correlation spectroscopy it is now possible to restrict the approximate size of soluble Abeta aggregates formed in the presence of both inhibitors from 3- to 15-mers.
DOI: 10.1074/jbc.M405914200
PubMed: 15322133
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002372
Links to Exploration step
pubmed:15322133Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.</title><author><name sortKey="Rzepecki, Petra" sort="Rzepecki, Petra" uniqKey="Rzepecki P" first="Petra" last="Rzepecki">Petra Rzepecki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry, Philipps-Universität Marburg, Hans-Meerwein-Strasse, 35032 Marburg, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Chemistry, Philipps-Universität Marburg, Hans-Meerwein-Strasse, 35032 Marburg</wicri:regionArea></affiliation></author><author><name sortKey="Nagel Steger, Luitgard" sort="Nagel Steger, Luitgard" uniqKey="Nagel Steger L" first="Luitgard" last="Nagel-Steger">Luitgard Nagel-Steger</name></author><author><name sortKey="Feuerstein, Sophie" sort="Feuerstein, Sophie" uniqKey="Feuerstein S" first="Sophie" last="Feuerstein">Sophie Feuerstein</name></author><author><name sortKey="Linne, Uwe" sort="Linne, Uwe" uniqKey="Linne U" first="Uwe" last="Linne">Uwe Linne</name></author><author><name sortKey="Molt, Oliver" sort="Molt, Oliver" uniqKey="Molt O" first="Oliver" last="Molt">Oliver Molt</name></author><author><name sortKey="Zadmard, Reza" sort="Zadmard, Reza" uniqKey="Zadmard R" first="Reza" last="Zadmard">Reza Zadmard</name></author><author><name sortKey="Aschermann, Katja" sort="Aschermann, Katja" uniqKey="Aschermann K" first="Katja" last="Aschermann">Katja Aschermann</name></author><author><name sortKey="Wehner, Markus" sort="Wehner, Markus" uniqKey="Wehner M" first="Markus" last="Wehner">Markus Wehner</name></author><author><name sortKey="Schrader, Thomas" sort="Schrader, Thomas" uniqKey="Schrader T" first="Thomas" last="Schrader">Thomas Schrader</name></author><author><name sortKey="Riesner, Detlev" sort="Riesner, Detlev" uniqKey="Riesner D" first="Detlev" last="Riesner">Detlev Riesner</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15322133</idno><idno type="pmid">15322133</idno><idno type="doi">10.1074/jbc.M405914200</idno><idno type="wicri:Area/PubMed/Corpus">002372</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002372</idno><idno type="wicri:Area/PubMed/Curation">002372</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002372</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.</title><author><name sortKey="Rzepecki, Petra" sort="Rzepecki, Petra" uniqKey="Rzepecki P" first="Petra" last="Rzepecki">Petra Rzepecki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry, Philipps-Universität Marburg, Hans-Meerwein-Strasse, 35032 Marburg, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Chemistry, Philipps-Universität Marburg, Hans-Meerwein-Strasse, 35032 Marburg</wicri:regionArea></affiliation></author><author><name sortKey="Nagel Steger, Luitgard" sort="Nagel Steger, Luitgard" uniqKey="Nagel Steger L" first="Luitgard" last="Nagel-Steger">Luitgard Nagel-Steger</name></author><author><name sortKey="Feuerstein, Sophie" sort="Feuerstein, Sophie" uniqKey="Feuerstein S" first="Sophie" last="Feuerstein">Sophie Feuerstein</name></author><author><name sortKey="Linne, Uwe" sort="Linne, Uwe" uniqKey="Linne U" first="Uwe" last="Linne">Uwe Linne</name></author><author><name sortKey="Molt, Oliver" sort="Molt, Oliver" uniqKey="Molt O" first="Oliver" last="Molt">Oliver Molt</name></author><author><name sortKey="Zadmard, Reza" sort="Zadmard, Reza" uniqKey="Zadmard R" first="Reza" last="Zadmard">Reza Zadmard</name></author><author><name sortKey="Aschermann, Katja" sort="Aschermann, Katja" uniqKey="Aschermann K" first="Katja" last="Aschermann">Katja Aschermann</name></author><author><name sortKey="Wehner, Markus" sort="Wehner, Markus" uniqKey="Wehner M" first="Markus" last="Wehner">Markus Wehner</name></author><author><name sortKey="Schrader, Thomas" sort="Schrader, Thomas" uniqKey="Schrader T" first="Thomas" last="Schrader">Thomas Schrader</name></author><author><name sortKey="Riesner, Detlev" sort="Riesner, Detlev" uniqKey="Riesner D" first="Detlev" last="Riesner">Detlev Riesner</name></author></analytic><series><title level="j">The Journal of biological chemistry</title><idno type="ISSN">0021-9258</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (metabolism)</term><term>Alzheimer Disease (pathology)</term><term>Amyloid beta-Peptides (chemistry)</term><term>Amyloid beta-Peptides (genetics)</term><term>Amyloid beta-Peptides (metabolism)</term><term>Animals</term><term>Centrifugation, Density Gradient</term><term>Humans</term><term>Hydrogen Bonding</term><term>Ligands</term><term>Models, Molecular</term><term>Molecular Structure</term><term>Peptide Fragments (chemistry)</term><term>Peptide Fragments (genetics)</term><term>Peptide Fragments (metabolism)</term><term>Protein Structure, Quaternary</term><term>Protein Structure, Secondary</term><term>Pyrazoles (chemistry)</term><term>Pyrazoles (metabolism)</term><term>Spectrometry, Fluorescence (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Centrifugation en gradient de densité</term><term>Fragments peptidiques ()</term><term>Fragments peptidiques (génétique)</term><term>Fragments peptidiques (métabolisme)</term><term>Humains</term><term>Liaison hydrogène</term><term>Ligands</term><term>Maladie d'Alzheimer (anatomopathologie)</term><term>Maladie d'Alzheimer (métabolisme)</term><term>Modèles moléculaires</term><term>Peptides bêta-amyloïdes ()</term><term>Peptides bêta-amyloïdes (génétique)</term><term>Peptides bêta-amyloïdes (métabolisme)</term><term>Pyrazoles ()</term><term>Pyrazoles (métabolisme)</term><term>Spectrométrie de fluorescence ()</term><term>Structure moléculaire</term><term>Structure quaternaire des protéines</term><term>Structure secondaire des protéines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Amyloid beta-Peptides</term><term>Peptide Fragments</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Amyloid beta-Peptides</term><term>Peptide Fragments</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Maladie d'Alzheimer</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Fragments peptidiques</term><term>Peptides bêta-amyloïdes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Alzheimer Disease</term><term>Amyloid beta-Peptides</term><term>Peptide Fragments</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Spectrometry, Fluorescence</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Fragments peptidiques</term><term>Maladie d'Alzheimer</term><term>Peptides bêta-amyloïdes</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Alzheimer Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Centrifugation, Density Gradient</term><term>Humans</term><term>Hydrogen Bonding</term><term>Ligands</term><term>Models, Molecular</term><term>Molecular Structure</term><term>Protein Structure, Quaternary</term><term>Protein Structure, Secondary</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Centrifugation en gradient de densité</term><term>Fragments peptidiques</term><term>Humains</term><term>Liaison hydrogène</term><term>Ligands</term><term>Modèles moléculaires</term><term>Peptides bêta-amyloïdes</term><term>Pyrazoles</term><term>Spectrométrie de fluorescence</term><term>Structure moléculaire</term><term>Structure quaternaire des protéines</term><term>Structure secondaire des protéines</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A new concept is introduced for the rational design of beta-sheet ligands, which prevent protein aggregation. Oligomeric acylated aminopyrazoles with a donor-acceptor-donor (DAD) hydrogen bond pattern complementary to that of a beta-sheet efficiently block the solvent-exposed beta-sheet portions in Abeta-(1-40) and thereby prevent formation of insoluble protein aggregates. Density gradient centrifugation revealed that in the initial phase, the size of Abeta aggregates was efficiently kept between the trimeric and 15-meric state, whereas after 5 days an additional high molecular weight fraction appeared. With fluorescence correlation spectroscopy (FCS) exactly those two, i.e. a dimeric aminopyrazole with an oxalyl spacer and a trimeric head-to-tail connected aminopyrazole, of nine similar aminopyrazole ligands were identified as efficient aggregation retardants whose minimum energy conformations showed a perfect complementarity to a beta-sheet. The concentration dependence of the inhibitory effect of a trimeric aminopyrazole derivative allowed an estimation of the dissociation constant in the range of 10(-5) m. Finally, electrospray ionization mass spectrometry (ESI-MS) was used to determine the aggregation kinetics of Abeta-(1-40) in the absence and in the presence of the ligands. From the comparable decrease in Abeta monomer concentration, we conclude that these beta-sheet ligands do not prevent the initial oligomerization of monomeric Abeta but rather block further aggregation of spontaneously formed small oligomers. Together with the results from density gradient centrifugation and fluorescence correlation spectroscopy it is now possible to restrict the approximate size of soluble Abeta aggregates formed in the presence of both inhibitors from 3- to 15-mers.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15322133</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>279</Volume><Issue>46</Issue><PubDate><Year>2004</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation></Journal><ArticleTitle>Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.</ArticleTitle><Pagination><MedlinePgn>47497-505</MedlinePgn></Pagination><Abstract><AbstractText>A new concept is introduced for the rational design of beta-sheet ligands, which prevent protein aggregation. Oligomeric acylated aminopyrazoles with a donor-acceptor-donor (DAD) hydrogen bond pattern complementary to that of a beta-sheet efficiently block the solvent-exposed beta-sheet portions in Abeta-(1-40) and thereby prevent formation of insoluble protein aggregates. Density gradient centrifugation revealed that in the initial phase, the size of Abeta aggregates was efficiently kept between the trimeric and 15-meric state, whereas after 5 days an additional high molecular weight fraction appeared. With fluorescence correlation spectroscopy (FCS) exactly those two, i.e. a dimeric aminopyrazole with an oxalyl spacer and a trimeric head-to-tail connected aminopyrazole, of nine similar aminopyrazole ligands were identified as efficient aggregation retardants whose minimum energy conformations showed a perfect complementarity to a beta-sheet. The concentration dependence of the inhibitory effect of a trimeric aminopyrazole derivative allowed an estimation of the dissociation constant in the range of 10(-5) m. Finally, electrospray ionization mass spectrometry (ESI-MS) was used to determine the aggregation kinetics of Abeta-(1-40) in the absence and in the presence of the ligands. From the comparable decrease in Abeta monomer concentration, we conclude that these beta-sheet ligands do not prevent the initial oligomerization of monomeric Abeta but rather block further aggregation of spontaneously formed small oligomers. Together with the results from density gradient centrifugation and fluorescence correlation spectroscopy it is now possible to restrict the approximate size of soluble Abeta aggregates formed in the presence of both inhibitors from 3- to 15-mers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rzepecki</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Philipps-Universität Marburg, Hans-Meerwein-Strasse, 35032 Marburg, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagel-Steger</LastName><ForeName>Luitgard</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Feuerstein</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Linne</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Molt</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Zadmard</LastName><ForeName>Reza</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Aschermann</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wehner</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schrader</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Riesner</LastName><ForeName>Detlev</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002499" MajorTopicYN="N">Centrifugation, Density Gradient</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006860" MajorTopicYN="N">Hydrogen Bonding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="Y">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="Y">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15322133</ArticleId><ArticleId IdType="doi">10.1074/jbc.M405914200</ArticleId><ArticleId IdType="pii">M405914200</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002372 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002372 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15322133
|texte= Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15322133" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |